NYSE:BMYPharmaceuticals
Is Hengrui’s US$15.2 Billion Alliance Reshaping the Investment Case for Bristol Myers Squibb (BMY)?
In May 2026, Hengrui Pharma and Bristol Myers Squibb entered global strategic collaboration and license agreements to advance a portfolio of 13 early-stage oncology, hematology and immunology programs, with potential deal value of up to US$15.20 billion including US$600.00 million upfront and further milestone payments and tiered royalties.
The cross-border structure, with each company swapping territorial rights and jointly discovering additional assets, signals a deeper two-way integration...